TCGA-BA-A4IG-01A-11R-A266-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.580
- MYC_TARGETS_V1+0.480
- G2M_CHECKPOINT+0.440
- OXIDATIVE_PHOSPHORYLATION+0.420
- MYC_TARGETS_V2+0.380
- SPERMATOGENESIS+0.380
- FATTY_ACID_METABOLISM+0.370
- DNA_REPAIR+0.290
- MTORC1_SIGNALING+0.280
- PEROXISOME+0.200
Top 10 suppressed
- ANGIOGENESIS-0.620
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.560
- INTERFERON_ALPHA_RESPONSE-0.480
- MYOGENESIS-0.430
- NOTCH_SIGNALING-0.430
- HEDGEHOG_SIGNALING-0.410
- APICAL_JUNCTION-0.370
- COAGULATION-0.370
- INTERFERON_GAMMA_RESPONSE-0.350
- INFLAMMATORY_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-A6V7-01A-12R-A34R-07 | — | — | 0.894 |
| 2 | 1ac3f1b2-5b83-470c-b1d3-d35d813f3e65 | — | — | 0.891 |
| 3 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.890 |
| 4 | TCGA-BB-8601-01A-11R-2403-07 | — | — | 0.887 |
| 5 | SRR2932839 | — | — | 0.882 |
| 6 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.881 |
| 7 | 96a00cc6-3880-4f03-a08d-73d284787971 | — | — | 0.881 |
| 8 | TCGA-P3-A5QF-01A-11R-A28V-07 | — | — | 0.877 |
| 9 | C3N-00555 | — | cohortSQ2 | 0.877 |
| 10 | TCGA-60-2719-01A-01R-0851-07 | — | cohortSQ1 | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.380 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |